secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001453687-25-000043
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics outlines 2025 priorities; Phase 3 MG trial to start in 1H25
--------------------------------------------------------------------------------

- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; primary endpoint is MG-ADL improvement ≥3 points at Month 4 vs placebo.
- Update Phase 2b MG data: average MG-ADL reduction of 5.5 at Month 4 (n=12); deepening responses over time; no need for preconditioning chemo.
- Phase 2 SLE trial of Descartes-08 enrolling; data readout expected in 2H25. SLE affects ~1.5M people in the US.
- Descartes-15 Phase 1 dose escalation ongoing in multiple myeloma; after Phase 1, will assess in autoimmune indications.
- Cash runway expected to support operations, including completion of Phase 3 MG trial, into mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/0001453687-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/rnac-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer